PMID- 33182025
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 88
DP  - 2020 Nov
TI  - The association between proton pump inhibitors use and clinical outcome of 
      patients receiving immune checkpoint inhibitors therapy.
PG  - 106972
LID - S1567-5769(20)32413-9 [pii]
LID - 10.1016/j.intimp.2020.106972 [doi]
AB  - BACKGROUND: The gut microbiome can mediate the efficacy of immune checkpoint 
      inhibitors (ICI). Meanwhile, proton pump inhibitors (PPI) can modulate the gut 
      microbiome significantly. However, the impact of PPI use on the clinical outcome 
      of ICI therapy remains unclear. METHODS: Searches of PubMed, EMBASE, and the 
      Cochrane Library were conducted to retrieve studies exploring the relationship 
      between PPI use and the clinical benefit of patients undergoing ICI therapy 
      through June 2020. The pooled hazard ratio (HR) and 95% confidence intervals 
      (CIs) were calculated to evaluate the influence of PPI use on overall survival 
      (OS) and progression-free survival (PFS). RESULTS: A total of seven studies were 
      eligible for our final analysis. There was no significant association between PPI 
      use and OS or PFS (PPI users versus non-users: HR for OS: 1.05, 95% CI: 
      0.79-1.40, P = 0.73; HR for PFS: 0.90, 95% CI: 0.66-1.23, P = 0.51). However, 
      subgroup analyses demonstrated that PPI use was related to a superior PFS of 
      melanoma patients (HR: 0.50, 95% CI: 0.28-0.91, P = 0.02) and an inferior PFS of 
      non-small cell lung cancer (NSCLC) patients (HR: 1.17, 95% CI: 1.05-1.31, 
      P = 0.006). CONCLUSIONS: Our present study indicates that PPI use is not 
      significantly associated with OS and PFS of patients undergoing ICI treatment. 
      However, concomitant PPI therapy may have a positive effect on melanoma patients 
      and a negative effect on NSCLC patients. It is advisable for clinical oncologists 
      to evaluate the necessity for PPI use when they treat patients with ICI therapy.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Li, Manyu
AU  - Li M
AD  - Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zeng, Chaofan
AU  - Zeng C
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Yao, Jiannan
AU  - Yao J
AD  - Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Ge, Yang
AU  - Ge Y
AD  - Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - An, Guangyu
AU  - An G
AD  - Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China. Electronic address: agybjcy@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200918
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Gastrointestinal Microbiome/drug effects
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*therapeutic use
MH  - Neoplasms/*drug therapy
MH  - Proton Pump Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Gastrointestinal microbiome
OT  - Immune checkpoint inhibitors
OT  - Meta-analysis
OT  - Proton pump inhibitors
OT  - Survival
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/11/14 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/11/13 01:01
PHST- 2020/07/16 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/11/13 01:01 [entrez]
AID - S1567-5769(20)32413-9 [pii]
AID - 10.1016/j.intimp.2020.106972 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2020 Nov;88:106972. doi: 10.1016/j.intimp.2020.106972. Epub 
      2020 Sep 18.